Medical Information

For Medical Information on OPSYNVI®(macitentan/
tadalafil), Please Contact Medical Information at Johnson & Johnson

Thank you for your interest in contacting Medical Information at Johnson & Johnson. We look forward to addressing your medical information questions for products marketed in the United States. For international inquiries, we must refer you to our affiliates.

To submit a medical information question related to a Johnson & Johnson product or to report a side effect or product complaint, please reach out to Medical Information at Johnson & Johnson via options listed below.

You can also report a side effect or product complaint of prescription drugs to the FDA. Visit
or call
.
Phone Icon

Phone:

Please call: 1-800-526-7736

Monday-Friday, 9 AM - 8 PM ET.

Laptop Icon

Online:

Medical Connect Logo
Mail Icon

Mail:

Johnson & Johnson, Medical Information

1125 Trenton-Harbourton Road

PO Box 200

Titusville, NJ 08560

†

OPSYNVI® and OPSUMIT® have identical list prices as of January 2025.

‡

When both drugs are covered on the same formulary tier by the patient's insurance.

6MWD=6-minute walk distance; BNP=brain natriuretic peptide; ERA=endothelin receptor antagonist; FC=Functional Class; NT-proBNP=N-terminal pro-brain natriuretic peptide; PAH=pulmonary arterial hypertension; PDE5i=phosphodiesterase type 5 inhibitor; PVR=pulmonary vascular resistance.

References: 1. OPSYNVI® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022;43(38):3618-3731. 3. Pulido T, Adzerikho I, Channick RN, et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818 and suppl 1-21. doi:10.1056/NEJMoal213917 4.  REVATIO® Prescribing Information. Pfizer. 5.  ADCIRCA® Prescribing Information. Eli Lily & Co. 6. Data on file. Johnson & Johnson and its affiliates. Master Price List. Accessed January 3, 2025. 7.  Data on file. Managed Markets Insights and Technology, LLC™, a trademark of MMIT, as of January 2025. 8.  Data on file. Johnson & Johnson and its affiliates. Potential OOP for PDE5i. May 7, 2025.